
|Videos|July 6, 2022
Dr. Garmezy on impact of antibody-drug conjugates on bladder cancer treatment paradigm
Author(s)Urology Times staff
“What’s really exciting over the next few years is how are these antibody-drug conjugates that are already FDA-approved going to partner with other current drugs that we can use to treat this disease, such as immunotherapy,” says Garmezy.
Advertisement
Benjamin Garmezy, MD, discusses the FDA-approved antibody-drug conjugates (ADCs) enfortumab vedotin (Padcev) and sacituzumab govitecan (Trodelvy) and the next steps with ADCs in the treatment paradigm for patients with urothelial carcinoma.
Garmezy is assistant director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5










